Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Aventis Consumer Products Combo Would Be Divested

This article was originally published in The Tan Sheet

Executive Summary

Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge

You may also be interested in...



Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now

Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company

Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now

Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company

Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now

Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company

Related Content

Topics

UsernamePublicRestriction

Register

PS096644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel